Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
Nuvation Bio Inc. (NUVB) Presents at H.C. Wainwright 4th Annual BioConnect Investor Conference Transcript
NUVB - Nuvation Bio Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$13.00
DETAILS
HIGH:
$17.00
LOW:
$10.00
MEDIAN:
$12.50
CONSENSUS:
$13.00
UPSIDE:
175.42%
Stock News
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
Thermo Fisher Scientific, the world leader in serving science, will now manufacture drug product for Nuvation Bio in the United States Move by Nuvation Bio further ensures critical drug supply for patients and providers NEW YORK, May 13, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific, the world leader in serving science, for IBTROZI® (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The transition was submitted as a supplement to the IBTROZI New Drug Application held by Nuvation Bio and is now complete.
Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Nuvation Bio Inc. (NUVB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Nuvation Bio Inc. (NYSE: NUVB)
NEW YORK, May 7, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Nuvation Bio Inc. (NYSE: NUVB) on behalf of the company's shareholders. The investigation seeks to determine whether Nuvation Bio Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
Application includes updated TRUST-I TKI-naïve median duration of response (mDOR) and median progression-free survival (mPFS) of more than 4 years, as well as TRUST-II TKI-pretreated mDOR of nearly 20 months FDA has assigned a target action date of January 4, 2027 NEW YORK, May 6, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) with updated data for IBTROZI ® (taletrectinib) in both TKI-naïve and TKI-pretreated advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) with a target action date of January 4, 2027. The submission, which fulfills an FDA post-marketing commitment and is intended to update the efficacy information provided in the IBTROZI label, includes an additional 10 months of data from the pivotal TRUST-I and TRUST-II studies as of an August 2025 data cutoff, further validating the overall clinical profile with long-term follow-up.
Nuvation Bio to Participate in Upcoming Investor Conferences
NEW YORK, May 5, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in fireside chats and one-on-one meetings at the following conferences: Bank of America Securities 2026 Healthcare Conference – fireside chat on Wednesday, May 13, 2026, at 8:00 a.m.
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Q1 2026 Earnings Call Transcript
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates
Nuvation Bio Inc. (NUVB) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.16 per share a year ago.
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI ® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-naïve, highlighting continued momentum in the first-line setting Presented newly updated clinical data demonstrating IBTROZI's impressive durability of response and progression-free survival in TKI-naïve and TKI-pretreated patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) at AACR 2026 Announced acquisition of Japan rights to safusidenib from Daiichi Sankyo, enabling global development and commercialization of promising investigational medicine Strong balance sheet with cash, cash equivalents, and marketable securities of $533.7 million as of March 31, 2026 Company to host a conference call today at 4:30 pm ET NEW YORK, May 4, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. "We are pleased with IBTROZI's ongoing launch trends in the first quarter of 2026, as we continue to deepen its adoption across lines of therapy and make significant progress in becoming the standard of care for people living with advanced ROS1-positive NSCLC.
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings Growth
Nuvation Bio (NUVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
Guidelines include the next-generation targeted therapy as a systemic option for patients with ROS1-positive non-small cell lung cancer with brain metastases NEW YORK, April 27, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that taletrectinib (IBTROZI®) has been added to the latest National Comprehensive Cancer Network® Clinical Practice Guidelines (NCCN Guidelines®) in Oncology for Central Nervous System (CNS) cancers, updated on April 24, 2026. Specifically, the NCCN Guidelines® for CNS Cancers now recommend taletrectinib (IBTROZI) as a systemic therapy option for ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) patients with brain metastases.
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
Analysis of longer-term pooled data from TRUST-I and TRUST-II demonstrated nearly 50 months median duration of response and 46.1 months median progression-free survival in TKI-naïve patients IBTROZI also demonstrated a high overall response rate in TKI-naïve patients at 89.8% Long-term pooled data highlighted in oral and poster presentations at AACR, and TRUST-I data simultaneously published in the Journal of Clinical Oncology, reinforce IBTROZI's manageable safety profile, with low rates of neurologic side effects and no new safety signals IBTROZI demonstrated robust CNS activity, with an intracranial response rate of 76.5% in TKI-naïve patients and 65.6% in TKI-pretreated patients with brain metastases Preclinical data presented at AACR showed taletrectinib's potential for suppressing TRKB-mediated lung cancer cell migration NEW YORK, April 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced results from a pooled analysis of long-term follow-up data from the pivotal TRUST-I and TRUST-II trials for IBTROZI® (taletrectinib) in patients with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The updated efficacy and safety results for both TKI-naïve and TKI-pretreated patients were presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 in oral and poster presentations.
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
NEW YORK, April 20, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, May 4, 2026, at 4:30 p.m. ET to discuss its financial results and business updates for the first quarter of 2026.
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)
200,000 Class A shares were sold for a transaction value of `$904,000 at around $4.52 per share on April 6, 2026. The sale accounted for 79.0% of Wentworth's direct Class A holdings, reducing direct ownership from 253,000 to 53,000 shares.
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Capricorn Fund Managers Ltd Makes New Investment in Nuvation Bio Inc. $NUVB
Capricorn Fund Managers Ltd bought a new position in shares of Nuvation Bio Inc. (NYSE: NUVB) in the undefined quarter, according to its most recent 13F filing with the SEC. The fund bought 1,588,854 shares of the company's stock, valued at approximately $14,236,000. Nuvation Bio accounts for approximately 3.4% of Capricorn Fund Managers
Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm
NEW YORK, April 2, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Nuvation Bio Inc. (NYSE: NUVB) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
With acquisition of Japan rights, Nuvation Bio now has global development and commercialization rights for safusidenib Agreement provides Nuvation Bio ownership of global clinical development program, inclusive of clinical trials, past and current data generation, and future publications NEW YORK, April 1, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the company has amended its existing exclusive license agreement for safusidenib with Daiichi Sankyo (TSE :4568) to include Japan rights, effectively securing exclusive global development and commercialization rights of the investigational medicine. The agreement, as amended, enables Nuvation Bio to expand its ongoing pivotal SIGMA study of safusidenib into Japan, and provides rights to all previously generated and future data to support further publication of safusidenib results in IDH1-mutant glioma.
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-centered global leading research-based pharmaceutical company working
Price Targets
Nuvation Bio price target raised to $13 from $11 at Truist
$13.00
(was $5.66)
Truist Financial
Nuvation Bio price target raised to $12 from $9 at RBC Capital
$12.00
(was $6.01)
Leonid Timashev
·
RBC Capital
Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright
$17.00
(was $6.52)
H.C. Wainwright
UBS Starts Nuvation Bio Inc (NUVB) at Neutral
$10.00
(was $8.49)
Michael Yee
·
UBS
Nuvation Bio price target raised to $18 from $10 at H.C. Wainwright
$18.00
(was $7.88)
H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Nuvation Bio Inc (NUVB)
$10.00
(was $8.04)
Robert Burns
·
H.C. Wainwright
Nuvation Bio initiated with a Buy at Truist
$11.00
(was $6.99)
Truist Financial
Nuvation Bio price target raised to $10 from $8 at Citizens JMP
$10.00
(was $7.29)
JMP Securities
Nuvation Bio price target raised to $8 from $6 at Citizens JMP
$8.00
(was $5.17)
JMP Securities
Nuvation Bio initiated with an Outperform at Citizens JMP
$6.00
(was $2.08)
Silvan Tuerkcan
·
JMP Securities
Nuvation Bio price target lowered to $7 from $8 at H.C. Wainwright
$7.00
(was $3.05)
Robert Burns
·
H.C. Wainwright
Nuvation Bio Inc (NUVB) PT Raised to $5 at RBC Capital
$5.00
(was $2.81)
Kennen MacKay
·
RBC Capital
Nuvation Bio Inc (NUVB) PT Raised to $8 at H.C. Wainwright on AnHeart deal
$8.00
(was $3.97)
Robert Burns
·
H.C. Wainwright
Jefferies Upgrades Nuvation Bio Inc (NUVB) to Buy
$10.00
(was $2.88)
Michael Yee
·
Jefferies
BTIG Upgrades Nuvation Bio Inc (NUVB) to Buy, has 'two potentially best-in-class drugs'
$5.00
(was $2.25)
Kaveri Pohlman
·
BTIG
Jefferies Downgrades Nuvation Bio to Hold, Lowers Price Target to $2
$2.00
(was $2.03)
Jefferies
HC Wainwright & Co. Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $14
$14.00
(was $4.78)
H.C. Wainwright